Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: Possible implications for opiate addiction
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Opioid drugs play important roles in the clinical management of pain, as well as in the development and treatment of drug abuse. The mu opioid receptor is the primary site of action for the most commonly used opioids, including morphine, heroin, fentanyl, and methadone. By sequencing DNA from 113 former heroin addicts in methadone maintenance and 39 individuals with no history of drug or alcohol abuse or dependence, we have identified five different single-nucleotide polymorphisms (SNPs) in the coding region of the mu opioid receptor gene. The most prevalent SNP is a nucleotide substitution at position 118 (A118G), predicting an amino acid change at a putative N-glycosylation site. This SNP displays an allelic frequency of approximately 10% in our study population. Significant differences in allele distribution were observed among ethnic groups studied. The variant receptor resulting from the A118G SNP did not show altered binding affinities for most opioid peptides and alkaloids tested. However, the A118G variant receptor binds β-endorphin, an endogenous opioid that activates the mu opioid receptor, approximately three times more tightly than the most common allelic form of the receptor. Furthermore, β-endorphin is approximately three times more potent at the A118G variant receptor than at the most common allelic form in agonist-induced activation of G protein-coupled potassium channels. These results show that SNPs in the mu opioid receptor gene can alter binding and signal transduction in the resulting receptor and may have implications for normal physiology, therapeutics, and vulnerability to develop or protection from diverse diseases including the addictive diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
McLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry
Basbaum, A. I., & Fields, H. L. (1984) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.07.030184.001521 · Cited by 2,687
A potent and selective endogenous agonist for the µ-opiate receptor
Zadina, J. E., Hackler, L., Ge, L.-J., & Kastin, A. J. (1997) · Nature · doi:10.1038/386499a0 · Cited by 1,311
Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas
Parma, J., Duprez, L., Sande, J. V., Cochaux, P., Gervy, C., Mockel, J., Dumont, J., & Vassart, G. (1993) · Nature · doi:10.1038/365649a0 · Cited by 918
Molecular cloning and functional expression of a mu opioid receptor from rat brain
Chen, Y., Mestek, A., Liu, J., Hurley, A., & Yu, L. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90214-3 · Cited by 810
Self-citationShenker, A., Laue, L., Kosugi, S., Merendino, J. J., Minegishi, T., & Cutler, G. B. (1993) · Nature · doi:10.1038/365652a0 · Cited by 745
Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel
Kubo, Y., Reuveny, E., Slesinger, P. A., Jan, Y. N., & Jan, L. Y. (1993) · Nature · doi:10.1038/364802a0 · Cited by 597
Pharmacological Mechanisms of Opioid Analgesics
Pasternak, G. W. (1993) · Clinical Neuropharmacology · doi:10.1097/00002826-199302000-00001 · Cited by 551
mu opiate receptor: cDNA cloning and expression.
Wang, J. B., Imai, Y., Eppler, C. M., Gregor, P., Spivak, C. E., & Uhl, G. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10230 · Cited by 407
Cited by
Molecular mechanisms of opioid receptor-dependent signaling and behavior
Al-Hasani, R., & Bruchas, M. R. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318238bba6 · Cited by 1,067
Kreek, M. J., Nielsen, D. A., Butelman, E. R., & LaForge, K. S. (2005) · Nature Neuroscience · doi:10.1038/nn1583 · Cited by 1,024
Self-citationdepue, R. A., & morrone-strupinsky, J. V. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000063 · Cited by 958
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802
Molecular Mechanisms and Regulation of Opioid Receptor Signaling
Law, P.-Y., Wong, Y. H., & Loh, H. H. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.389 · Cited by 661
Eap, C. B., Buclin, T., & Baumann, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00003 · Cited by 599
Mu Opioids and Their Receptors: Evolution of a Concept
Pasternak, G. W., & Pan, Y.-X. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007138 · Cited by 578
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialAllelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
Zhang, Y., Wang, D., Johnson, A. D., Papp, A. C., & Sadée, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504942200 · Cited by 563
The neurobiology and genetics of impulse control disorders: Relationships to drug addictions
Brewer, J. A., & Potenza, M. N. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.043 · Cited by 511
Low back pain in older adults: risk factors, management options and future directions
Wong, A. Y., Karppinen, J., & Samartzis, D. (2017) · Scoliosis and Spinal Disorders · doi:10.1186/s13013-017-0121-3 · Cited by 456
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451
“This substitution has been reported to increase binding of -endorphin and increase functional activity in vitro.(20) In addition, early reports have suggested that the 15% to 25% of humans(22,23) who carry the Asp40 allele show a greater response to alcohol,(24,25) greater endocrine response to opioid antagonists,(26)…”
BackgroundOpioid dependence and addiction during opioid treatment of chronic pain
Ballantyne, J. C., & LaForge, S. K. (2007) · Pain · doi:10.1016/j.pain.2007.03.028 · Cited by 447
Kirchheiner, J., Schmidt, H., Tzvetkov, M., Keulen, J.-T., Lötsch, J., Roots, I., & Brockmöller, J. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500406 · Cited by 439
The genetic mediation of individual differences in sensitivity to pain and its inhibition
Mogil, J. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7744 · Cited by 434
Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O’Brien, C. P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1423 · Cited by 405
“A number of polymorphisms have been identified for the gene encoding the mu opiate receptor, and one of them, the Asp40 variant, has been found to have high affinity for beta endorphin in vitro (45) and altered function during in”
BackgroundPharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Kreek, M. J., Bart, G., Lilly, C., Laforge, K. S., & Nielsen, D. A. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.1 · Cited by 391
Self-citationSmith, Y. R., Stohler, C. S., Nichols, T. E., Bueller, J. A., Koeppe, R. A., & Zubieta, J.-K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5223-05.2006 · Cited by 378
Relatively strong automatic appetitive action‐tendencies in male carriers of the OPRM1 G‐allele
Wiers, R. W., Rinck, M., Dictus, M., & Van Den Wildenberg, E. (2009) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2008.00454.x · Cited by 377
“receptor binding or expression (Bond et al. 1998; van der Zwaluw et al. 2007; Zhang et al. 2007).”
BackgroundPharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
Kreek, M. J., LaForge, K. S., & Butelman, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd897 · Cited by 374
Self-citationFillingim, R. B., Kaplan, L., Staud, R., Ness, T. J., Glover, T. L., Campbell, C. M., Mogil, J. S., & Wallace, M. R. (2005) · The Journal of Pain · doi:10.1016/j.jpain.2004.11.008 · Cited by 362
Mutant G-protein-coupled receptors as a cause of human diseases
Schöneberg, T., Schulz, A., Biebermann, H., Hermsdorf, T., Römpler, H., & Sangkuhl, K. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.008 · Cited by 337
Sehgal, N. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/es67 · Cited by 326
Somogyi, A. A., Barratt, D. T., & Coller, J. K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100095 · Cited by 324
Tolerance and Withdrawal From Prolonged Opioid Use in Critically Ill Children
Anand, K. J. S., Willson, D. F., Berger, J., Harrison, R., Meert, K. L., Zimmerman, J., Carcillo, J., Newth, C. J. L., Prodhan, P., Dean, J. M., et al. (2010) · Pediatrics · doi:10.1542/peds.2009-0489 · Cited by 321
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent
Compton, P., Charuvastra, V. C., & Ling, W. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00200-3 · Cited by 311
Chou, W.-Y., Wang, C.-H., Liu, P.-H., Liu, C.-C., Tseng, C.-C., & Jawan, B. (2006) · Anesthesiology · doi:10.1097/00000542-200608000-00016 · Cited by 315
Reyes-Gibby, C. C., Shete, S., Rakvåg, T., Bhat, S. V., Skorpen, F., Bruera, E., Kaasa, S., & Klepstad, P. (2007) · Pain · doi:10.1016/j.pain.2006.10.023 · Cited by 313
Ray, L. A., & Hutchison, K. E. (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000148114.34000.b9 · Cited by 310
Rahim-Williams, B., Riley, J. L., Williams, A. K. K., & Fillingim, R. B. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2012.01336.x · Cited by 305
A genetic determinant of the striatal dopamine response to alcohol in men
Ramchandani, V. A., Umhau, J., Pavon, F. J., Ruiz-Velasco, V, Margas, W., Sun, H., Damadzic, R., Eskay, R., Schoor, M., Thorsell, A., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.56 · Cited by 298
Sia, A. T., Lim, Y., Lim, E. C. P., Goh, R. W. C., Law, H. Y., Landau, R., Teo, Y.-Y., & Tan, E. C. (2008) · Anesthesiology · doi:10.1097/aln.0b013e318182af21 · Cited by 297
Chou, W. ‐., Yang, L. ‐., Lu, H. ‐., Ko, J. ‐., Wang, C. ‐., Lin, S. ‐., Lee, T. ‐., Concejero, A., & Hsu, C. ‐. (2006) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2006.01058.x · Cited by 296
Hoehe, M. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2895 · Cited by 290
The Interpersonal Dimension of Borderline Personality Disorder: Toward a Neuropeptide Model
Stanley, B., & Siever, L. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09050744 · Cited by 289
Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective
Dumas, E. O., & Pollack, G. M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9056-1 · Cited by 269
Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264
Ray, L. A., & Hutchison, K. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1069 · Cited by 258
Beyer, A., Koch, T., Schröder, H., Schulz, S., & Höllt, V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02340.x · Cited by 258
KREEK, M. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06683.x · Cited by 258
Self-citationL??tsch, J., Skarke, C., Liefhold, J., & Geisslinger, G. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443140-00003 · Cited by 256
Hatsukami, D. K., Stead, L. F., & Gupta, P. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60871-5 · Cited by 227
Kroslak, T., LaForge, K. S., Gianotti, R. J., Ho, A., Nielsen, D. A., & Kreek, M. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04738.x · Cited by 213
Self-citationZhou, H., Rentsch, C. T., Cheng, Z., Kember, R. L., Nunez, Y. Z., Sherva, R. M., Tate, J. P., Dao, C., Xu, K., Polimanti, R., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1206 · Cited by 186
Variation at the mu-opioid receptor gene ( OPRM1 ) influences attachment behavior in infant primates
Barr, C. S., Schwandt, M. L., Lindell, S. G., Higley, J. D., Maestripieri, D., Goldman, D., Suomi, S. J., & Heilig, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710225105 · Cited by 191
“Wand GS, et al. (2002) The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade.”
InfluentialDevelopment of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Single nucleotide polymorphisms related to hpa axis reactivity
DeRijk, R. H. (2009) · NeuroImmunoModulation · doi:10.1159/000216192 · Cited by 140
Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin
Shi, J., Hui, L., Xu, Y., Wang, F., Huang, W., & Hu, G. (2002) · Human Mutation · doi:10.1002/humu.9026 · Cited by 140
“The c.118A→G transition does not independently affect the heroin addiction, although it changed the affinity of mu receptor to beta-endorphin in vitro (Bond et al., 1998).”
BackgroundResultInfluentialTan, E.-C., Lim, E. C., Teo, Y.-Y., Lim, Y., Law, H.-Y., & Sia, A. T. (2009) · Molecular Pain · doi:10.1186/1744-8069-5-32 · Cited by 133
“plausible if 118G alters the binding affinity and subsequent downstream activities of the receptor as suggested by Bond et al [ 25 ].”
BackgroundKling, M. A., Carson, R. E., Borg, L., Zametkin, A., Matochik, J. A., Schluger, J., Herscovitch, P., Rice, K. C., Ho, A., Eckelman, W. C., et al. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39007-x · Cited by 119
Self-citationTroisi, A., Frazzetto, G., Carola, V., Di Lorenzo, G., Coviello, M., D'Amato, F. R., Moles, A., Siracusano, A., & Gross, C. (2011) · Social Neuroscience · doi:10.1080/17470919.2010.482786 · Cited by 118
“An in vitro study demonstrated that the expression of the minor 118G allele causes a threefold increase in binding affinity for the endogenous opioid peptide beta-endorphin and enhances G protein-coupled potassium channel activation (Bond et al., 1998).”
BackgroundMethodHeilig, M., Thorsell, A., Sommer, W. H., Hansson, A. C., Ramchandani, V. A., George, D. T., Hommer, D., & Barr, C. S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.018 · Cited by 117
Barr, C. S., Schwandt, M., Lindell, S. G., Chen, S. A., Goldman, D., Suomi, S. J., Higley, J. D., & Heilig, M. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.369 · Cited by 105
Pharmacotherapy in the Treatment of Addiction: Methadone
Kreek, M. J., Borg, L., Ducat, E., & Ray, B. (2010) · Journal of Addictive Diseases · doi:10.1080/10550881003684798 · Cited by 108
“19 This variant is functionally different from the prototype in molecular and cell biological studies.”
BackgroundSelf-citationRen, Z.-Y., Shi, J., Epstein, D. H., Wang, J., & Lu, L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1472-0 · Cited by 101
“2000), a possibility supported by animal and human studies of genetic polymorphisms (Bond et al. 1998; Mogil 1999; Mogil et al. 1996).”
BackgroundHuman kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction
Gerra, G., Leonardi, C., Cortese, E., D'Amore, A., Lucchini, A., Strepparola, G., Serio, G., Farina, G., Magnelli, F., Zaimovic, A., et al. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30510 · Cited by 90
“The A118G single nucleotide polymorphism (SNP) that was found to alter binding and signal transduction in the resulting receptor may have implications for vulnerability to develop or protection from diverse psychiatric disorders including the addictive diseases [Bond et al., 1998].”
BackgroundBruehl, S., Burns, J. W., Chung, O. Y., & Chont, M. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.12.003 · Cited by 88
Drug dependence and the endogenous opioid system
Gerrits, M. A. F. M., Lesscher, H. B. M., & van Ree, J. M. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.003 · Cited by 82
“However, the endogenous opioid h-endorphin bound with a three times higher affinity to the A118G Aopioid receptor, and h-endorphin was more potent at this receptor in activating G-protein coupled potassium channels (Bond et al., 1998).”
BackgroundAssociation of the mu-opioid receptor gene with smoking cessation
Munafò, M. R., Elliot, K. M., Murphy, M. F. G., Walton, R. T., & Johnstone, E. C. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500432 · Cited by 78
Ray, L. A., Bujarski, S., MacKillop, J., Courtney, K. E., Monti, P. M., & Miotto, K. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01916.x · Cited by 75
“This nonsynonymous mutation results in an amino acid change from asparagine to aspartic acid, which in turn is thought to increase binding affinity for b-endorphin (Bond et al., 1998).”
Higham, J. P., Barr, C. S., Hoffman, C. L., Mandalaywala, T. M., Parker, K. J., & Maestripieri, D. (2011) · Behavioral Neuroscience · doi:10.1037/a0022695 · Cited by 69
“Functionally similar nonsynonymous OPRM1 SNPs have arisen and been maintained in humans (A118G; Bond et al., 1998) and rhesus macaques (C77G; Miller et al., 2004).”
InfluentialPain tolerance predicts human social network size
Johnson, K. V.-A., & Dunbar, R. I. M. (2016) · Scientific Reports · doi:10.1038/srep25267 · Cited by 65
Hermann, D., Hirth, N., Reimold, M., Batra, A., Smolka, M. N., Hoffmann, S., Kiefer, F., Noori, H. R., Sommer, W. H., Reischl, G., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.145 · Cited by 64
“…that alcohol dependence and treatment response to naltrexone is associated with the G-allele of the non-synonymous single-nucleotide polymorphism (SNP) rs1799971 (Asn40Asp, A118G), which is located in the first exon of the MOR gene (OPRM1) (Bond et al., 1998; Heilig et al., 2011; Ray et al., 2012).”
BackgroundNielsen, D. A., Ho, A., Bahl, A., Varma, P., Kellogg, S., Borg, L., & Kreek, M. J. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.12.022 · Cited by 61
“…M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript (n = 145), meeting the same criteria we have used in previous genetic studies (Bond et al., 1998; Levran et al., 2008), had 1) no alcohol intoxication or illicit drug use (except possibly cannabis) in the last 30 days, 2) no…”
MethodSelf-citationZhou, Y., Proudnikov, D., Yuferov, V., & Kreek, M. J. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.015 · Cited by 58
Self-citationTreatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Kakko, J., von Wachenfeldt, J., Svanborg, K. D., Lidström, J., Barr, C. S., & Heilig, M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.001 · Cited by 41
(2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.012 · Cited by 34
Association of μ-opioid receptor gene (OPRM1) haplotypes with postoperative nausea and vomiting
Sugino, S., Hayase, T., Higuchi, M., Saito, K., Moriya, H., Kumeta, Y., Kurosawa, N., Namiki, A., & Janicki, P. K. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3987-9 · Cited by 28
Lee, M. R., Gallen, C. L., Zhang, X., Hodgkinson, C. A., Goldman, D., Stein, E. A., & Barr, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024203 · Cited by 27
“The polymorphism was originally shown to confer a 3-fold increase in affinity for the endogenous ligand, ß-Endorphin [4], although more recent studies have shown the effects of the G allele on affinity for ß-”
BackgroundWhat the alcohol doctor ordered from the neuroscientist
Heilig, M., & Leggio, L. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.07.023 · Cited by 25
Curley, J. P. (2011) · Behavioral Neuroscience · doi:10.1037/a0022939 · Cited by 19
Metadata
- Authors
- Bond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., Tischfield, J. A., Kreek, M. J., & Yu, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-08-04
- Volume
- 95
- Issue
- 16
- Pages
- 9608-9613
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2012743573
- Cited by
- 1,074
- References
- 41
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.